NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

荷爾蒙補充療法(HRT)的全球市場(2020年∼2027年)

Global Hormone Replacement Therapy (HRT) Market - 2020-2027

出版商 DataM Intelligence 商品編碼 967424
出版日期 按訂單生產 內容資訊 英文
商品交期: 請詢問到貨日
價格
荷爾蒙補充療法(HRT)的全球市場(2020年∼2027年) Global Hormone Replacement Therapy (HRT) Market - 2020-2027
出版日期: 按訂單生產內容資訊: 英文
簡介

全球荷爾蒙補充療法(HRT)市場成長,由於對女性停經後的問題的認識高漲,新的給藥系統造成醫藥品開發增加,老年人口的增加伴隨的荷爾蒙不平衡障礙等要素,推動市場成長。

該市場過去數年大幅度發展,在預測期間內預計大幅度成長。由於荷爾蒙的不平衡問題的頻率增加,老年人及新生兒的人口的增加,這些疾病預計增加。但,荷爾蒙補充療法,有消化不良,憂鬱症,體液儲存,頭痛等幾個副作用,可能妨礙該治療方法的採用。

本報告提供全球荷爾蒙補充療法(HRT)市場的相關調查,市場機會和影響,成長及阻礙因素,各產品、疾病類型、給藥途徑、流通管道、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 市場定義和概要

第3章 摘要整理

  • 各產品的市場明細
  • 各疾病類型的市場明細
  • 各給藥途徑的市場明細
  • 各流通管道的市場明細
  • 各地區的市場明細

第4章 市場動態

  • 影響市場的要素
    • 成長要素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 產業分析

  • 波特的五力分析
  • 開發平台分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 COVID-19分析

  • 市場上的Covid-19分析
  • Covid-19的價格動態
  • 需求與供給的頻譜
  • 大流行時的市場相關的政府舉措
  • 製造商策略性舉措
  • 結論

第7章 市場分析:各產品

  • 簡介
  • 市場規模分析及與前一年同期比較成長分析
  • 市場魅力指數
    • 甲狀腺荷爾蒙
    • 雌激素荷爾蒙
    • 睪固酮荷爾蒙
    • 人體生長荷爾蒙

第8章 市場分析:各疾病類型

  • 簡介
  • 市場規模分析及與前一年同期比較成長分析
  • 市場魅力指數
    • 甲狀腺機能低下症
    • 閉經
    • 男性的性腺功能降低症
    • 生長激素缺乏症
    • 其他

第9章 市場分析:各給藥途徑

  • 簡介
  • 市場規模分析及與前一年同期比較成長分析
  • 市場魅力指數
    • 口服
    • 非口服
    • 經皮
    • 其他

第10章 市場分析:各流通管道

  • 簡介
  • 市場規模分析及與前一年同期比較成長分析
  • 市場魅力指數
    • 醫院藥局
    • 零售藥局和藥妝店
    • 線上藥局
    • 其他

第11章 市場分析:各地區

  • 簡介
  • 市場規模分析及與前一年同期比較成長分析
  • 市場魅力指數
  • 北美
  • 歐洲
  • 南美
  • 亞太地區
  • 中東和非洲

第12章 競爭情形

  • 競爭模式
  • 市場定位/佔有率分析
  • 合併和收購分析

第13章 企業簡介

  • Abbott Laboratories
    • 企業概要
    • 產品系列、概要
    • 要點
    • 財務概要
  • Pfizer, Inc.
  • Bayer AG
  • Novartis AG
  • Allergan Plc
  • Novo Nordisk A/S
  • Mylan NV
  • F. Hoffmann-La Roche
  • Eli Lilly and Company
  • Noven Pharmaceuticals, Inc.

第14章 重要考察

第15章 DataM

  • 附錄
  • 關於本公司、服務
  • 諮詢方式
目錄

Market Overview

The global hormone replacement therapy (HRT) market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Hormone replacement therapy (HRT) is a technique for replacing and replenishing hormones in the human body, which are at inadequate levels than those required for the normal physiology of the human body. Hormone replacement therapy helps to balance the estrogen and progesterone levels during or near menopause. During menopause, hormonal therapy or menopausal hormone therapy, hormone replacement therapy helps to relieve hot flashes, sweating, and other symptoms of menopause. The HR therapy has also been proved to prevent bone loss and reduce fracture in postmenopausal women. Systemic hormone therapy which comes in pill, cream, spray form, skin patch, or gel are one of the most effective treatments for the relief of menopausal hot flashes and night sweats.

Market Dynamics

The hormone replacement therapy market growth is driven some of the major factors such as growing awareness on post-menopausal issues among women, increasing drug development with novel delivery systems, and hormonal imbalance disorders with growing geriatric population.

Rising hormonal imbalance disorders with a growing geriatric population drive the HRT market growth

Hormonal imbalance disorders, with a growing geriatric population, is one of the major factors driving the growth of the HRT market. With several hormonal changes, the female body predominantly gets affected by the natural process of ageing, leads to abnormalities and diseases. Some of the common problems include fatigue, weight gain, memory decline, low libido, ageing appearance, and muscle loss.

The most frequent consequence of age-related hormonal changes occurs in cases related to menopause. The global average onset age for menopause among women is approximately 50 years. In women, the production levels of estrogen and progesterone decrease significantly by the age of 50 years and above. This decrease in production levels of estrogen and progesterone are compensated by the pituitary gland, with the increased production of follicle-stimulating hormone (FSH). This is physically manifested in women in the form of post-menopause symptoms, that include flush.

Increasing Development in the Hormone Replacement Therapy

The hormone replacement therapy market has observed significant development over the past few years and is expected to grow significantly during the forecast period. The increasing frequencies of hormonal lopsidedness issue and expanding aged and the neonatal populace these sicknesses are foreseen to advance development. The rising interest of hormone replacement therapy is driven by the existence of routinely observed details, growing technological progression in the field of drug delivery frameworks, and rising awareness among patients. Menopausal females frame the biggest segment influencing the market and subsequently, rising female populace between the age gathering of 45 to 59 and expanding the scope of the menopausal window are anticipated to push development.

In January 2020, a new menopause health service has launched in California that offers women remote consultations and, for the first time, mail-order prescriptions of menopause hormone replacement therapies. The telemedicine platform, called CurieMD, offers consumers video consultation with a board-certified midlife health practitioner (free at launch, and $39 for follow-up appointments). The FDA-approved bio-identical hormone treatments on offer come as oral tablets, vaginal creams and oral contraceptive pills, and are offered as quarterly payment plans.

Side-effects and Risks associated with HRT might hamper the market growth

Hormone Replacement Therapy has several side effects such as indigestion, depression, fluid retention, headache, among others. These side-effects are anticipated to hamper the adoption of this therapy.

Hormone replacement therapy might cause some risks for people with uncontrolled hypertension, or high blood pressure, thrombosis or blood clots, high levels of triglycerides in the blood, stroke, heart disease, breast cancer, and gallbladder disease.

Also, according to a UK-based NICE finding, hormone replacement therapy is associated with breast cancer risk if the drugs progesterone and oestrogen are taken in combination. Prolonged consumption of HRT drugs might lead to increased risk of blood clots also. Every 1,000 women taking HRT tablets for 7.5 years, less than two will develop a blood clot, as per some studies.

Epidemiology

Hypothyroidism:

According to the National Health and Nutrition Examination Survey (NHANES 1999-2002), of 4392 individuals reflecting the US population reported hypothyroidism (defined as TSH levels exceeding 4.5 mIU/L) in 3.7% of the population. Hypothyroidism is most common in women with small body size at birth and low body mass index during childhood.

Iodine deficiency as a cause of hypothyroidism is more common in less-developed countries. Routine supplementation of salt, flour, and other food staples with iodine has decreased the rates of iodine deficiency.

The World Health Organization (WHO) data from 130 countries taken from January 1994 through December 2006 found inadequate iodine nutrition in 30.6% of the population. The WHO recommends urinary iodine concentrations between 100 and 199 弮g/L in the general population and a range of 150-249 弮g/L in pregnant women.

The frequency of hypothyroidism, goiters, and thyroid nodules increases with age. Hypothyroidism is most prevalent in elderly populations, with 2-20% of older age groups having some form of hypothyroidism. The Framingham study found hypothyroidism (TSH > 10 mIU/L) in 5.9% of women and 2.4% of men older than 60 years. In NHANES 1999-2002, the odds of having hypothyroidism were five times greater in persons aged 80 years and older than in individuals aged 12-49 years.

The NHANES 1999-2002 reported that the prevalence of hypothyroidism was higher in whites (5.1%) and Mexican Americans than in African Americans (1.7%). The African Americans tend to have lower median TSH values.

COVID-19 Impact Analysis

The COVID-19 is affecting the global economy by directly affecting production and demand, by disturbing the supply chain and market disruption, and by its financial impact on firms and financial markets. The global hormone replacement therapy (HRT) market has impacted from the COVID-19 pandemic, as stakeholders are increasingly searching for newer approaches towards diagnosing and curing patients affected by the COVID-19.

Exogenous estrogen and testosterone therapies have a therapeutic potential to mitigate the damaging inflammatory response to SARS-CoV-2 without hampering the immune system's response to the virus as corticosteroids do. The use of immune-modulating drugs to block inflammatory markers' receptors to mitigate the amplified and tissue-damaging immune response of SARS-CoV-2 (eg, anarka [an IL-1 receptor blocker] and tocilizumab and sarilumab [IL-6 receptor antagonists]). However, there are concerns about these agents' possible adverse effects on patients' immune function.

According to research from King's College London, University of Liverpool and Zoe Global Limited, aimed at contributing to an evaluation of the potential for estrogen treatment in COVID-19, by examining the presence of an association between high estrogen levels and lower levels of COVID-19 infection and severity in women.

The researchers showed that the rate of predicted COVID-19 was higher in post-menopausal women on HRT, who also showed a higher frequency of related symptoms but not of hospitalization. HRT use was associated with a trend towards lower respiratory support and positive testing. The age-group analysis showed the effects to be highest in the 55-60 year age group.

The researchers also looked at the effect of exogenous estrogen in the form of the combined oral contraceptive pill (COCP) on COVID-19-related symptoms and infection, and the effect of hormone replacement therapy (HRT) on COVID-19 positivity and symptom severity in women past menopause.

There is need for future research to examine whether hormone replacement therapy may have a pharmacotherapeutic role in treating older adults diagnosed with COVID-19.

Market Segment Analysis

The global hormone replacement therapy (HRT) market is segmented based on the product, disease type, route of administration, and distribution channel.

On the basis of Disease, Menopause is Expected to Growth at High CAGR over the Forecast Period

Menopause is the stage which marks the end of the menstrual cycles. It is diagnosed after 12 months without a menstrual period. Menopause can happen in at the age of 40 or 50. Menopause is a natural biological process. Hormone replacement therapy improves the quality of life and prolongs life for elderly women, whether it is initiated at menopause or much later. The therapy helps elderly women maintain their estrogen levels.

Menopause segment growth is expected to increase in future as the geriatric population globally is increasing. According to a 2017 report by the United Nations, the percentage of the population aged 60 years or above is expected to increase from 12.7% in 2017 to 21.3% by 2050. This change is expected to be more prevalent in developed countries. Hence, as both men and women age, the application of HRT in elderly women is expected to grow, which will help the market growth.

As per the American Congress of Obstetricians and Gynecologists, about 6,000 women reach menopause daily. The presence of several branded and generic drugs and growing awareness among women are expected to be the vital impact of rendering drivers.

By Product, Estrogen Segment is Expected to Hold Largest Market Share During the Forecast Period

On the basis of product, the HRT market is segmented into therapies for estrogen, testosterone, human growth hormone, and thyroid hormones. Among these, the estrogen hormone replacement therapy segment accounted for the largest market share in 2019, as estrogen-based products have been studied to generate the largest number of prescriptions. Estrogen replacement therapy is used in women during post-menopause or hysterectomy, which helps them to maintain the hormonal balance.

On the other hand, the human growth hormone therapy is expected to grow at the fastest CAGR over the forecast period due to the increasing incidences of growth deficiencies, especially in infants. For instance, as per a survey organized by the WHO, around 15 million newborns are born premature, and around 85% of these infants are not fully developed. In adults, the hormone therapy is provided for conditions such as short bowel syndrome and pituitary tumours.

Market Geographical Analysis

North America region holds the largest market share in the global Hormone Replacement Therapy market

North America region is dominating the global hormone replacement therapy market accounted for the largest market share in 2019, owing to the growing geriatric population in the United States and Canada. As per the National Institutes of Health (NIH), almost half of all the post-menopausal women in the United States reported having used hormone replacement therapy at least once in their life. The conjugated equine estrogens (CEE)/bazedoxifene tablet, a combination of estrogen and a selective estrogen receptor modulator, is available in the U.S. for menopausal VMS treatment and osteoporosis prevention. Overall, the market for hormone replacement therapy in the United States is scheduled for high growth over the forecast period, due to growing adoption of hormone replacement therapy among women, for both post-menopausal and menopause management.

Asia Pacific is the fastest growing market in the global hormone replacement therapy market

The Asia Pacific HRT market is expected to witness the fastest growth over the forecast period from 2020 to 2027. Increasing awareness levels and rising focus of healthcare providers on the eradication of hormonal deficiencies are expected to boost the growth of the market within the region.

Market Competitive Landscape

The hormone replacement therapy market is consolidated and competitive. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, Pfizer, Inc. , Bayer AG, Novartis AG, Allergan Plc, Novo Nordisk A/S, Mylan NV, F. Hoffmann-La Roche, Eli Lilly and Company, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the hormone replacement therapy market globally. For instance, in October 2018, TherapeuticsMD received its third FDA approval for a menopause remedy that combines two bioidentical hormones. The agency cleared Bijuva, an oral softgel that contains estradiol and progesterone, two commonly used hormone therapies, to alleviate menopause symptoms such as hot flashes. TherapeuticsMD's ingredients are artificially produced but chemically identical to hormones made naturally by women's bodies.

Abbott Laboratories

Overview:

Abbott Laboratories headquarters in the United States is a global medical devices and health care company. The company has four business segments: medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013. In March 2020, Abbott received emergency use authorization (EUA) from the FDA for a 2019-nCoV test to help mitigate the COVID-19 pandemic.

Product Portfolio:

Why Purchase the Report?

  • Visualize the composition of the hormone replacement therapy (HRT) market segmentation by product, disease type, route of administration, and distribution channel highlighting the key commercial assets and players.
  • Identify commercial opportunities in hormone replacement therapy (HRT) market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of hormone replacement therapy (HRT) market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global hormone replacement therapy (HRT) market report would provide an access to an approx. 69 market data table, 67 figures and 250 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Hormone Replacement Therapy (HRT) Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Hormone Replacement Therapy (HRT) Market - Market Definition and Overview

3. Global Hormone Replacement Therapy (HRT) Market - Executive Summary

  • 3.1. Market Snippet by Product
  • 3.2. Market Snippet by Disease Type
  • 3.3. Market Snippet by Route of Administration
  • 3.4. Market Snippet by Distribution Channel
  • 3.5. Market Snippet by Region

4. Global Hormone Replacement Therapy (HRT) Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Awareness on Post-menopausal Issues among Women
      • 4.1.1.2. Increasing Drug Development with Novel Delivery Systems
      • 4.1.1.3. XX
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Hormone Replacement Therapy
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Hormone Replacement Therapy (HRT) Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Pipeline Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. Global Hormone Replacement Therapy (HRT) Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Hormone Replacement Therapy (HRT) Market - By Product

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment
  • 7.3. Market Attractiveness Index, By Product Segment
    • 7.3.1. Thyroid Hormone Replacement Therapy*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Estrogen Hormone Replacement Therapy
    • 7.3.3. Testosterone Hormone Replacement Therapy
    • 7.3.4. Human Growth Hormone Replacement Therapy

8. Global Hormone Replacement Therapy (HRT) Market - By Disease Type

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
  • 8.3. Market Attractiveness Index, By Disease Type Segment
    • 8.3.1. Hypothyroidism*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Menopause
    • 8.3.3. Male Hypogonadism
    • 8.3.4. Growth Hormone Deficiency
    • 8.3.5. Others

9. Global Hormone Replacement Therapy (HRT) Market - By Route of Administration

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.3. Market Attractiveness Index, By Route of Administration Segment
    • 9.3.1. Oral*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Parenteral
    • 9.3.3. Transdermal
    • 9.3.4. Others

10. Global Hormone Replacement Therapy (HRT) Market - By Distribution Channel

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 10.3. Market Attractiveness Index, By Distribution Channel Segment
    • 10.3.1. Hospital Pharmacies*
      • 10.3.1.1. Introduction
      • 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 10.3.2. Retail Pharmacies and Drugstores
    • 10.3.3. Online Pharmacy
    • 10.3.4. Others

11. Global Hormone Replacement Therapy (HRT) Market - By Region

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 11.3. Market Attractiveness Index, By Region
  • 11.4. North America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. U.S.
      • 11.4.7.2. Canada
      • 11.4.7.3. Mexico
  • 11.5. Europe
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. Germany
      • 11.5.7.2. U.K.
      • 11.5.7.3. France
      • 11.5.7.4. Italy
      • 11.5.7.5. Spain
      • 11.5.7.6. Rest of Europe
  • 11.6. South America
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.6.7.1. Brazil
      • 11.6.7.2. Argentina
      • 11.6.7.3. Rest of South America
  • 11.7. Asia Pacific
    • 11.7.1. Introduction
    • 11.7.2. Key Region-Specific Dynamics
    • 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.7.7.1. China
      • 11.7.7.2. India
      • 11.7.7.3. Japan
      • 11.7.7.4. Australia
      • 11.7.7.5. Rest of Asia Pacific
  • 11.8. Middle East and Africa
    • 11.8.1. Introduction
    • 11.8.2. Key Region-Specific Dynamics
    • 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Global Hormone Replacement Therapy (HRT) Market - Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Global Hormone Replacement Therapy (HRT) Market- Company Profiles

  • 13.1. Abbott Laboratories*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Pfizer, Inc.
  • 13.3. Bayer AG
  • 13.4. Novartis AG
  • 13.5. Allergan Plc
  • 13.6. Novo Nordisk A/S
  • 13.7. Mylan NV
  • 13.8. F. Hoffmann-La Roche
  • 13.9. Eli Lilly and Company
  • 13.10. Noven Pharmaceuticals, Inc.

LIST NOT EXHAUSTIVE

14. Global Hormone Replacement Therapy (HRT) Market - Premium Insights

15. Global Hormone Replacement Therapy (HRT) Market - DataM

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us